Three step high-dose chemotherapy in poor prognosis non-Hodgkin lymphoma.

被引：0
|
作者：
Ballestrero, A
Clavio, M
Ferrando, F
Secondo, V
Basta, P
Gonella, R
Garuti, A
Miglino, M
Pierri, I
Canepa, L
Beltrami, G
Vallebella, E
Ghio, R
Gobbi, M
Patrone, F
机构：
[1] Univ Genova, Sez Oncol & Ematol DIML, Genoa, Italy
[2] OC Galliera, Div Med, Genova, Italy
来源：
BONE MARROW TRANSPLANTATION | 1998年 / 21卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
613
引用
收藏
页码：S177 / S177
页数：1
相关论文
共 50 条
  • [41] Overweight as an adverse prognostic factor for non-Hodgkin's lymphoma patients receiving high-dose chemotherapy and autograft
    C Tarella
    D Caracciolo
    P Gavarotti
    C Argentino
    F Zallio
    P Corradini
    D Novero
    C Magnani
    A Pileri
    Bone Marrow Transplantation, 2000, 26 : 1185 - 1191
  • [42] Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's lymphoma: Randomized phase III EORTC study
    Kluin-Nelemans, HC
    Zagonel, V
    Anastasopoulou, A
    Bron, D
    Roozendaal, KJ
    Noordijk, EM
    Musson, H
    Teodorovic, I
    Maes, B
    Carbone, A
    Carde, P
    Thomas, J
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2001, 93 (01): : 22 - 30
  • [43] Autologous blood stem cell transplantation as initial therapy in patients with poor prognosis non-Hodgkin's lymphoma.
    Delage, R
    Desjardins, L
    Lacroix, L
    Lesnerance, B
    Nevill, T
    Roy, J
    Leblond, PF
    Demers, C
    Lyonnais, J
    Petitclerc, C
    Hewitt, A
    Berg, R
    Cantin, G
    BLOOD, 1996, 88 (10) : 468 - 468
  • [44] Survival benefit front high-dose therapy with autologous blood progenitor-cell transplantation in poor-prognosis non-Hodgkin's lymphoma
    Pettengell, R
    Radford, JA
    Morgenstern, GR
    Scarffe, JH
    Harris, M
    Woll, PJ
    Deakin, DP
    Ryder, D
    Wilkinson, PM
    Crowther, D
    JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (02) : 586 - 592
  • [45] Dose-dense chemotherapy for aggressive non-Hodgkin lymphoma
    Anderson-Reitz, Lowell
    CANCER NURSING, 2006, 29 (03) : 198 - 206
  • [46] High dose sequential chemotherapy with PBPC autograft as primary treatment in low-intermediate grade non-Hodgkin's lymphoma.
    Tarella, C
    Caracciolo, D
    Corradini, P
    Gavarotti, P
    Zallio, F
    Bianchi, A
    Novero, D
    Rossi, G
    Pileri, A
    BONE MARROW TRANSPLANTATION, 1998, 21 : S177 - S177
  • [47] Sequential PET using 18F-FDG predicts outcome after high-dose chemotherapy and stem cell transplantation in non-Hodgkin's lymphoma.
    Cremerius, U
    Fabry, U
    Wildberger, JE
    Zimny, M
    Nowak, B
    Osieka, R
    Buell, U
    JOURNAL OF NUCLEAR MEDICINE, 2002, 43 (05) : 263P - 263P
  • [48] Central nervous system relapse following high dose chemotherapy with autologous stem cell transplant for aggressive non-Hodgkin lymphoma.
    Pohlman, B
    Summers, K
    Jarvis, J
    Brown, S
    Kuczkowski, E
    Rybicki, L
    Kalaycio, M
    Sobecks, R
    Andresen, S
    Bolwell, B
    BLOOD, 2003, 102 (11) : 725A - 725A
  • [49] Tolerability and safety using fotemustine or thiotepa-based high-dose chemotherapy regimen in Hodgkin and non-Hodgkin lymphoma: a centre report
    Angarano, R.
    Carella, A. M.
    Merla, E.
    Greco, M. M.
    Cascavilla, N.
    BONE MARROW TRANSPLANTATION, 2017, 52 : S338 - S338
  • [50] A high serum soluble interleukin-2 receptor level is associated with a poor prognosis of aggressive and indolent non-Hodgkin's lymphoma.
    Goto, H
    Tsurumi, H
    Ino-Shimomura, Y
    Sawada, M
    Yamada, T
    Kasahara, S
    Hara, T
    Kojima, Y
    Takami, T
    Moriwaki, H
    BLOOD, 2002, 100 (11) : 349A - 349A
12345